Millennium Management
ACRS icon

Millennium Management’s Aclaris Therapeutics ACRS Stock Holding History

Millennium Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-100,000
Closed -$685K – 6019
2023
Q3 		$685K Buy
+100,000
New +$855K ﹤0.01% 4457

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management's ACRS Position: Q1 2026 in Review

Millennium Management reduced its Aclaris Therapeutics (ACRS) stake by 28% in Q1 2026, selling an estimated $1M and leaving 756,127 shares worth $2.84M. The position accounts for ﹤0.01% of the portfolio, ranked #3522.

Millennium Management first reported a position in ACRS in Q1 2017 and has held it in 32 quarters since. The position peaked at $13.5M in Q3 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Millennium Management held 756,127 shares of Aclaris Therapeutics worth $2.84M as of Q1 2026.
  • Millennium Management sold 297,119 Aclaris Therapeutics shares in Q1 2026, an estimated $1M.
  • Aclaris Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3522 holding.
  • Millennium Management first reported a position in Aclaris Therapeutics in Q1 2017 and has held it in 32 quarters since.
  • Millennium Management's Aclaris Therapeutics position peaked at $13.5M in Q3 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.